Company: AEMD
Filing Date: 2025-07-25
Form Type: DRS
Source: 0001683168-25-005397
Chunk: 44

Company: AETHLON MEDICAL INC
Filing Date: 2025-07-25
Form: DRS
Chunk 44
---
 | our ability to successfully complete our clinical trials;                                                      |
| · | our ability to identify and work with large-scale contracts with medical device manufacturers;                 |
| · | our ability to manufacture the Hemopurifier;                                                                   |
| · | the impact of inflation, recent bank failures                                                                  
 and military conflicts, as well as related political and economic responses                                    
 on our business;                                                                                               |
| · | our ability to attract and retain executive management and directors;                                          |
| · | the regulatory landscape for our products,                                                                     
 domestically and internationally and our ability to comply with changing government regulations;               |
| · | our ability to comply with the continued                                                                       
 listing requirements of the Nasdaq Capital Market and maintain our listing on the Nasdaq Capital Market;       |
| · | our expectations regarding growth potential for our business in the organ transplant setting;                  |
| · | our ability to secure regulatory clearance                                                                     
 or approval, domestically and internationally, for the clinical use of our products;                           |
| · | any estimates regarding expenses, future revenue and capital requirements;                                     |
| · | our ability to protect our proprietary technology through patent protection;                                   |
| · | our product liability exposure;                                                                                |
| · | our ability to sustain and manage growth, including our ability to develop new products and enter new markets; |
| · | our ability to achieve sufficient market acceptance of any of our products or product candidates; and          |
| · | our expected net proceeds from this offering and the use of the net proceeds from this offering.               |

In some cases, you can identify
these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “continue,” “seek,”
“project,” “should,” “will,” “would” or the negative of those terms, and similar expressions.
You should be aware that the occurrence of any of the events discussed under the heading “Risk Factors” in this prospectus
and any documents incorporated by reference herein could substantially harm our business, operating results and financial condition and
that if any of these events occurs, it could adversely affect the value of an investment in our common stock. In addition, statements
that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based
upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis